| 2-AG | 2-arachidonylglycerol |
| AA-5HT | N-arachidonoylserotonin |
| AC | Adenylyl cyclase |
| AEA | Anandamide |
| cAMP | Cyclic AMP |
| CB1 | Cannabinoid 1 |
| CB2 | Cannabinoid 2 |
| CMS | Chronic mild stress |
| CNS | Central nervous system |
| CUS | Chronic unpredictable stress |
| DAGL | Diacylglycerol lipase |
| ECS | Endocannabinoid system |
| FAAH | Fatty acid amide hydrolase |
| FST | Forced swim test |
| HPA | Hypothalamic–pituitary–adrenal |
| MAGL | Monoacylglycerol lipase |
| MAPK | Mitogen-activated protein kinase |
| MDD | Major depressive disorder |
| MDE | Major depressive episode |
| NAPE | N-arachidonoyl-phosphatidyl-ethanolamine |
| NAPE-PLD | N-acylphosphatidylethanolamine-selective phospholipase D |
| OBX | Olfactory bulbectomized |
| PFC | Prefrontal cortex |
| PKA | Protein kinase A |
| PRISMA | Preferred reporting items for systematic reviews and meta-analyses |
| qPCR | Quantitative polymerase chain reaction |
| SSRI | Selective serotonin reuptake inhibitor |
| TCA | Tricyclic antidepressant |
| Δ9-THC | Δ9-tetrahydrocannabinol |
| TRPV1 | Transient receptor potential vanilloid type-1 |
| TST | Tail suspension test |
| WKY | Wistar–Kyoto |